2022-03-11FDA approves olaparib for adjuvant treatment of high-risk early breast cancerTrial OlympiADrug Lynparza (olaparib) · PARP inhibitorConditionBreast
2018-10-16FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancerTrial EMBRACADrug TALZENNA (talazoparib) · PARP inhibitorConditionBreast
2018-01-12FDA approves olaparib for germline BRCA-mutated metastatic breast cancerTrial OlympiADDrug Lynparza (olaparib) · PARP inhibitorConditionBreast